A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)

Inclusion Criteria: 1. Age 18-75, male or non-pregnant female 2. Evidence of non-symptomatic ischemia, stable or non-stable angina pectoris or past MI 3. Target lesion is primary and de-novo coronary artery disease 4. The target lesion length ≤ 60 mm, diameter 2.25mm-5.0mm (visually estimated) 5. Lesion diameter stenosis ≥70% (visually estimated) 6. For each target lesion, same stent implantation only 7. Acceptable candidate for coronary artery bypass grafting (CABG) 8. Understand the study purpose, willing to participate and sign the letter of consent, agrees to the follow-up visits including a 9 month angiographic follow-up Exclusion Criteria: 1. Acute MI within 1 week 2. Chronic total occlusion(TIMI 0), left main lesion, intervention-required three-vessel lesions, branch vessel diameter ≥ 2.5mm and bypass lesion 3. More than 3 stents required 4. Patients refuse to be implanted stent 5. Calcified lesion failed in pre-dilation, twisted lesion and lesion unsuitable for stent delivery and expansion 6. In-stent restenosis 7. Planned percutaneous coronary intervention (PCI) within 3 months post procedure 8. Other stents implanted within 1 year 9. Severe heart failure (NYHA above III) or left ventricle ejection fraction (EF) \<40% 10. Renal function damage, blood creatinine \> 176.82 μmol/L 11. Bleeding tendency, active peptic ulcer disease, cerebral or subarachnoid hemorrhage, cerebral apoplexy within half year and contraindication for any anti-platelet or anticoagulation agents 12. Allergic to drugs or agents used in stent or protocol (PLGA, sirolimus, aspirin, clopidogrel, contrast agent, cobalt, nickel, chromium, iron, wolfram et. al.) 13. Life expectation \< 12 months 14. Have not reached the primary end point when participating in other trial 15. Poor compliance to the protocol 16. Heart implantation cases